Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Study of AK156 in Primary Osteoporosis Patients

NCT01522521 is registered in ClinicalTrials.gov with Asahi Kasei Therapeutics Corporation as lead sponsor.

NCT NCT01522521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01522521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Study of AK156 in Primary Osteoporosis Patients
Lead sponsor
Asahi Kasei Therapeutics Corporation
Phase
Phase 3
Overall status
Completed
Start date
February 29, 2012
Completion date
January 31, 2015
Enrollment
600 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis